STOCK TITAN

Artivion (AORT) CCO receives stock units, sells shares to cover taxes

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Artivion, Inc. Chief Commercial Officer John E. Davis reported two equity transactions in company common stock. On March 2, 2026, he acquired 28,845 shares at $0.00 per share, issued upon vesting of performance stock units from a February 2025 grant. On March 3, 2026, 4,573 shares were sold at an average price of $37.7756 per share to cover tax withholding obligations in a non-discretionary “sell to cover” transaction. Following these movements, Davis held 230,794 shares of Artivion common stock directly.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Davis John E

(Last) (First) (Middle)
1655 ROBERTS BLVD., NW

(Street)
KENNESAW GA 30144

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ARTIVION, INC. [ AORT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/02/2026 A 28,845(1) A $0 235,367 D
Common Stock 03/03/2026 S 4,573(2) D $37.7756 230,794 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents performance stock units granted on February 28, 2025. One third (1/3) were issued on March 2, 2026. The remaining shares earned in connection with the February 2025 grant will be eligible to vest and be issued as follows: one third (1/3) on February 28, 2027; and one third (1/3) on February 28, 2028, assuming employment on the relevant vesting date.
2. These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction.
Remarks:
/s/ John E. Davis 03/04/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Artivion (AORT) report for John E. Davis?

Artivion (AORT) reported that Chief Commercial Officer John E. Davis received 28,845 common shares from vesting performance stock units, then sold 4,573 shares. The sale was executed solely to cover tax withholding obligations via a non-discretionary “sell to cover” transaction.

How many Artivion (AORT) shares did John E. Davis sell and at what price?

John E. Davis sold 4,573 Artivion shares at an average price of $37.7756 per share. According to the disclosure, this sale was made only to satisfy tax withholding obligations related to vested performance stock units through a pre-arranged “sell to cover” mechanism.

What stock award did John E. Davis receive from Artivion (AORT)?

John E. Davis received 28,845 Artivion common shares at $0.00 per share upon vesting of performance stock units granted in February 2025. One-third of that grant vested and was issued on March 2, 2026, with remaining tranches subject to future vesting dates.

Why were some of John E. Davis’s Artivion (AORT) shares sold?

The filing states that 4,573 shares were sold to pay tax withholding obligations arising from vested performance stock units. This was a non-discretionary “sell to cover” transaction, meaning shares were automatically sold to fund required taxes, not as an elective sale.

How many Artivion (AORT) shares does John E. Davis hold after these transactions?

After the reported transactions, John E. Davis directly holds 230,794 shares of Artivion common stock. This figure reflects the issuance of 28,845 shares from vesting performance stock units and the sale of 4,573 shares to satisfy related tax withholding obligations.

What is the vesting schedule for John E. Davis’s Artivion performance stock units?

The performance stock units were granted in February 2025. One-third was issued on March 2, 2026, while the remaining shares are eligible to vest in two equal parts on February 28, 2027 and February 28, 2028, assuming continued employment on each vesting date.
Artivion, Inc.

NYSE:AORT

View AORT Stock Overview

AORT Rankings

AORT Latest News

AORT Latest SEC Filings

AORT Stock Data

1.72B
44.00M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
KENNESAW